Similar to AstraZeneca's Caprelsa, which is also approved in this setting, the label states that for patients in whom the 'rearranged during transfection' (RET) mutation status is not known or is negative, a possible lower benefit should be considered…
written on 26.03.2014
Exelixis's oncology ambitions on track with European Cometriq approval
